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Abstract  
AIM: To assess the mean serum C-reactive protein concentrations among farmers and office controls, and further 
examined its relation to exposure duration, smoking habit, as well as presence or absence of COPD.  
METHODS: A cross-sectional survey was performed including examined group (EG), composed of agricultural 
workers (87 crop - EG1 and 83 dairy farmers - EG2), and control group (CG) composed by 80 office workers. 
Evaluation of subjects included a questionnaire on chronic respiratory symptoms, lung function tests, COPD 
diagnostics, and measurement of CRP serum concentrations.  
RESULTS: Serum CRP concentrations were raised in stable COPD patients independent of smoking habit or 
exposure duration. The mean CRP serum concentrations were higher in the subjects of EG1 and EG2 compared 
with those in CG, but without statistical significance. This count for mean CRP serum concentrations in subjects of 
EG1 and EG2 exposed more than 20 years and for those in smokers in all three groups as well. The mean CRP 
serum concentrations were significantly higher in subjects with COPD within EG1 (P=0.049) and EG2 (P=0.040), 
while those in CG were not.  
CONCLUSION: Data obtained suggest that systemic inflammation is present in farmers with COPD and CRP is 
an important biomarker in COPD in means of reflecting disease severity and prognosis of exposed farmers. 
 
 
 
 
 
Introduction 
 
Chronic obstructive pulmonary disease 
(COPD) is a major worldwide health problem with 
increasing prevalence and incidence. Although 
cigarette smoking is the most commonly encountered 
risk factor for COPD worldwide, some genetic and 
environmental risk factors are also well-identified in 
the disease pathogenesis. Still, it is well-known that 
nonsmokers may also develop chronic airflow 
obstruction [1].  
Chronic obstructive pulmonary disease 
(COPD) is a complex chronic inflammatory disease of 
the lungs involving several types of inflammatory cells 
and a variety of inflammatory mediators. The 
relationship between these cell types, cytokines, and 
the sequence of events that concludes with 
progressive airflow limitation and destruction of lung 
parenchyma remains largely unknown [2]. Although 
primarily affecting the lungs, the chronic inflammatory 
process of COPD does have systemic repercussions. 
Inflammatory markers, including C-reactive protein 
(CRP), lipopolysaccharide binding protein, the soluble 
TNF transmembrane receptor 75 (sTNF-R75), and 
soluble adhesion molecules are increased in the 
systemic circulation of patients with COPD [3-5]. 
 Systemic inflammation is determined by 
measurement of the CRP serum concentration and is 
present in patients with small airways obstruction. Sin 
et al. [6] reported that the withdrawal of inhaled 
corticosteroids resulted in a significant increase in 
CRP levels. 
Burning wood, animal dung, crop residues 
and coal in open fires or improper stoves may lead to 
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serious indoor air pollution. The indoor air pollution 
resulting from crop or dairy farming is an important 
risk factor for COPD especially in developing 
countries worldwide [7]. The chronic inflammation in 
COPD, orchestrated by multiple inflammatory cells 
and mediators in the airways and the lung tissues, is 
induced by inhalation of noxious gases and particulate 
matter. This persistent inflammatory response in the 
lung is also associated with a significant systemic 
inflammatory response yielding adverse clinical 
outcomes, so-called systemic effects of COPD [8]. 
Although the origin of systemic inflammation present 
in COPD remains poorly understood, and correlations 
in the regulation of inflammation in the pulmonary and 
systemic compartments are not well-documented yet, 
it is established that some inflammatory markers are 
risen in systemic circulation [8,9]. Of the blood-based 
biomarkers, C-reactive protein (CRP) has shown the 
greatest promise [10]. In COPD patients increased 
CRP levels are associated with poor lung function, 
reduced exercise capacity and worse quality of life as 
well as being a significant predictor of all-cause 
mortality [11-14]. As well as COPD itself, smoking, 
which is the most commonly encountered risk factor 
for the disease is also responsible for the rise in 
serum CRP levels [15]. Though to our knowledge the 
effect of crop and dairy farming exposure, potentially 
initiating the inflammatory process in the lungs of 
COPD patients, on serum CRP levels has not been 
studied in our setting previously. The growing 
awareness of COPD is a complex disease involving 
several organs with an established low-grade 
systemic inflammation, biomarkers have been more 
focus of interest in clarifying the pathogenesis and 
progression of COPD as well as in designing new 
therapeutic targets and models for the disease [14]. 
Based on the current knowledge that COPD is a 
multicomponent systemic disease with elevated 
serum CRP levels and that smoking itself leads to 
rising in CRP levels, the present study was 
undertaken. With the study, the authors aim to 
determine the relationship between serum CRP levels 
and well-known clinical parameters in COPD 
considering the impact of smoking behaviour, farming 
exposure duration and its characteristics. 
In the actual study we have assessed the 
mean CRP serum concentrations among crop and 
diary farmers and office controls, and further 
examined its relation to exposure duration, smoking 
habit, as well as presence or absence of COPD. 
 
 
Subjects and Methods 
 
Study design and setting 
We have performed a cross-sectional 
research in the Center for Respiratory Functional 
Diagnostics at the Institute for Occupational Health of 
Republic of Macedonia, Skopje - WHO Collaborating 
Center for Occupational Health and GA2LEN 
Collaborating Center within the period September 
2014 and April 2015. 
 
Subjects 
The survey included workers employed at 
agricultural enterprise divided into two groups: 
examined group (EG), composed of agricultural 
workers (crop and dairy farmers), and control group 
(CG) composed by office workers within the same 
enterprise.  
EG consists of 170 subjects, while CG has 80 
examinees. For the study purposes, and depending 
on the main agricultural activity, subjects were divided 
into two groups, examined group 1 (EG1) and 
examined group 2 (EG2). 
 EG1 comprised 87 crop farmers (mean age = 
53.4 ± 7.8 years) engaged in crop farming (mean 
duration of exposure 22.9 ± 7.8 years) with main 
activities composed of cultivating crops and 
vegetables, planting, digging, use of mechanized 
equipment, irrigation, and pesticide handling. They 
were exposed to various respiratory agents: dust, 
inappropriate climate, fumes, vapours and pesticides.  
 EG2 consists of 83 dairy farmers (mean age = 
52.6 ±8.7 years) employed as dairy farmers (mean 
duration of exposure 23.7 ±7.6 years), working inside 
confinement buildings, and exposed to: dust, 
inappropriate microclimate conditions, chemical 
hazards, vapors, gases, heavy manual work, animal 
contact, unfavorable body positions, and repetitive 
hand movements. Their main occupational activities 
were: preparation of fodder feeding and animal meals, 
milking, staying in the barn, preparation of straw, and 
hay making, cattle rising, as well as taking care of milk 
hygiene and animal health. Also, a similar group of 80 
office workers (mean age = 52.7 ±8.2 years) with no 
exposure to respiratory agents, matched for age, 
duration of employment, daily smoking and 
socioeconomic status was studied as a control.  
 The Institute’s ethics committee has approved 
the content of our study protocol, whereas each 
examined subject was informed and gave written 
consent before any involvement in the study. 
 
Questionnaire 
All study subjects were interviewed by the 
standardized questionnaire, including questions on 
work history, respiratory symptoms in the last 12 
months, and smoking habit. 
 Chronic respiratory symptoms in the last 12 
months (a cough, phlegm, dyspnea, wheezing, and 
chest tightness) were obtained using the European 
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Community for Coal and Steel questionnaire (ECCS-
87), and the European Community Respiratory Health 
Survey (ECRHS) questionnaire [16, 17].  
  Classification of smoking status was done 
according to the World Health Organization (WHO) 
guidelines on definitions of smoking status [18]. 
 Daily smoker was defined as a subject who 
smoked at the time of the field survey at least once a 
day, except on days of religious fasting. Among daily 
smokers, lifetime cigarette smoking and the daily 
mean of cigarettes smoked were also assessed. 
Pack-years smoked were calculated according to the 
actual recommendations [19]. Ex-smoker was defined 
as a formerly daily smoker, no longer smokes. 
 Passive smoking or exposure to 
environmental tobacco smoke (ETS) was defined as 
the exposure of a person to tobacco combustion 
products from smoking by others [20]. 
 
Spirometry 
All study subjects underwent spirometry 
testing, performed by spirometer Ganshorn 
SanoScope LF8 (Ganshorn Medizin Electronic GmbH, 
Germany), measuring forced vital capacity (FVC), 
forced expiratory volume in one second (FEV1), 
FEV1/FVC ratio, and maximal expiratory flow at 50%, 
75%, and 25-75% of FVC (MEF50, MEF75, and 
MEF25-75, respectively), by recording the best result 
from three measurements of the values of FEV1 
within 5% of each other. The results were expressed 
as percentages of the predicted values according to 
the European Community for Coal and Steel (ECCS) 
norms [21]. 
 
Diagnostic criteria for COPD 
According to the actual recommendations by 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), COPD is defined by post-bronchodilator 
FEV1/FVC ratio lower than 0.70 in subjects with 
dyspnea, chronic cough and/or a cough with phlegm 
[22]. Measurement of CRP serum concentrations as 
markers of inflammation. Mean CRP serum 
concentrations are measured by chemiluminescent 
immunoassay method with Immulite 1000 in subjects 
with chronic respiratory symptoms and/or spirometric 
impairment. CRP serum concentrations < 5 mg/L are 
within the normal range [23].  
 
Statistical analysis 
We have analyzed the data using Statistica 
for Windows version 7. Continuous variables were 
expressed as mean values with standard deviation 
and categorical variables as numbers and 
percentages. The comparison of mean CRP serum 
concentrations was performed by independent-
samples T-test. A P-value of less than 0.05 was 
considered statistically significant. 
 
Results 
 
Table 1 gives an overview of the demographic 
and overall characteristics of the subjects within the 
examined and control groups. 
Table 1: Demographic and overall characteristics of the study 
subjects 
Variable EG1 (n = 87) EG2 (n = 83) CG (n = 80) 
Gender / М/F ratio 3.6 2.6 2.7 
Age / years 53.4  7.8 52.6  8.7 52.7  8.2 
BMI / kg m
-2
 25.1  3.5 25.4  3.6 26.2  3.7 
Duration of employment / years 29.2  8.9 26.3  10.1 25.3  9.8 
Exposure duration / years 22.9  7.8 23.7  7.6 / 
Active (daily) smokers 45 (51.7%) 39 (46.9%) 39 (48.7%) 
Smoking experience / years 19.7  8.1 18.9  7.6 19.2  7.8 
Cigarettes / day 15.4  7.3 14.6  6.8 14.8 ± 7.2 
Ex-smokers 12 (13.8%) 9 (10.8%) 12 (15%) 
Passive smokers 11 (12.6%) 8 (9.6%) 7 (8.7%) 
Numerical data are expressed as mean values with standard deviations; frequencies of 
active, passive, and ex-smokers are given as number and percent of subjects with certain 
variable.М: males; F: females; BMI: body mass index. 
 
Table 2 shows the frequencies of COPD 
symptoms (dyspnea, chronic cough and phlegm) 
negative BD tests, post-bronchodilator FEV1/FVC less 
than 0.70 and frequency of COPD in subjects of EG1, 
EG2 and CG. 
Table 2: Frequency of COPD symptoms, negative BD tests, 
post-bronchodilator FEV1/FVC less than 0.70 and COPD in 
subjects of EG1, EG2 and CG 
Variable EG1 (n = 87) EG2 (n = 83) CG (n = 80) 
    
Respiratory symptoms within 
the last 12 months 
23 (26.4%) 24 (28.9%) 15 (18.8%) 
Negative BD test 11 (12.6%) 9 (10.8%) 5 (6.3%) 
Post-bronchodilator test 
FEV1/FVC < 0.70 
7 (8.1%) 8 (9.6%) 4 (5%) 
COPD 6 (6.9%) 7 (8.4%) 3 (3.8%) 
Data are given as number and percent of subjects with a certain variable. 
 
For the study purposes, we have examined 
the marker of chronic inflammation - CRP (C-reactive 
protein) among subjects in the three groups having 
one or more chronic respiratory symptoms and/or 
spirometric impairments. 
 
CRP serum concentrations 
The mean CRP serum concentrations were 
higher in EG1 compared to CG, but without statistical 
significance (Table 3). 
Table 3: Mean CRP serum concentrations in subjects of EG1 
and CG 
 EG1 
(n = 35) 
CG 
(n = 15) 
P-value* 
CRP (mg/L) 3.5 ± 2.4 3.1 ± 2.2 0.590 
Data are given as means with standard deviation. *Tested with t-test for independent 
samples. 
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The mean CRP serum concentrations were 
higher in EG2 compared to CG, but statistical 
significance was not yet reached (Table 4). 
Table 4: Mean CRP serum concentrations in subjects of EG2 
and CG 
 EG2 
(n = 32) 
CG  
(n = 15) 
P-value* 
CRP (mg/L) 3.6 ± 2.8 3.1 ± 2.2 0.529 
Data are given as means with standard deviation. *Tested with t-test for independent 
samples.  
 
Table 5 shows the mean CRP serum 
concentrations in subjects of EG1 with exposure 
duration less or equal to 20 years and over 20 years.  
Table 5: Mean CRP serum concentrations in subjects of EG1 
according to job exposure duration 
 Exposed > 20 years 
(n = 24) 
Exposed ≤ 20 years  
(n = 11) 
P-value* 
CRP (mg/L) 3.7 ± 2.8 3.2 ± 2.2 0.646 
Data are given as means with standard deviation. * Tested with t-test for independent 
samples. 
 
The mean CRP serum concentrations were 
higher in subjects of EG1 exposed longer than 20 
years, compared to those exposed less than 20 years, 
but without statistical significance.  
Table 6: Mean CRP serum concentrations in subjects of EG2 
according to job exposure duration 
 Exposed > 20 years 
(n = 22) 
Exposed ≤ 20 years  
(n = 10) 
P-value* 
CRP (mg/L) 3.9 ± 2.9 3.4 ± 2.2 0.653 
Data are given as means with standard deviation. *Tested with t-test for independent 
samples. 
 
Table 6 gives an overview of mean CRP 
serum concentrations in subjects of EG2 with duration 
of exposure less or equal to 20 years and over 20 
years. The mean CRP serum concentrations were 
non-significantly higher in subjects of EG2 exposed 
longer than 20 years, compared to those exposed less 
than 20 years. The mean CRP serum concentrations 
in subjects of all three groups depending on the 
smoking habit are given in Table 7. 
Table 7: Mean CRP serum concentrations in subjects of EG1, 
EG2, and CG depending on smoking habit  
Variable EG1 (n = 35) P* EG2 (n = 32) P* CG (n = 15) P* 
 21 vs 14  19 vs 13  Nine vs 6  
CRP in active 
smokers 
CRP in non-smokers 
3.71 ± 2.6 
3.3 ± 2.1 
NS 
0.705 
3.9 ± 3.1 
3.4 ± 2.3 
NS 
0.613 
2.9 ± 2.1 
3.3 ± 2.7 
NS 
0.708 
Data are given as means with standard deviation. * Tested with t-test for independent 
samples. 
 
The mean CRP serum concentrations were 
higher in smokers within the three groups, but without 
significant difference between smokers and non-
smokers. Mean CRP serum concentrations in all three 
groups due to the presence or absence of COPD are 
shown in Table 8. 
Table 8: Mean CRP concentrations in subjects of EG1, EG2, 
and CG due to the presence or absence of COPD 
Variable EG1 (n = 35) P* 
EG2 (n = 
32) 
P* CG (n = 15) P* 
 Six vs 29  
Seven vs 
25 
 Three vs 12  
CRP in subjects with 
COPD 
CRP in subjects 
without COPD 
6.5 ± 4.9 
 
3.5 ± 2.8 
0.049 
6.8 ± 4.9 
 
3.6 ± 2.9 
0.040 
5.9 ± 3.9 
 
3.1 ± 2.3 
0.117 
Data are given as means with standard deviation. *Tested with t-test for independent 
samples. 
The mean CRP serum concentrations were 
significantly higher in subjects with COPD within EG1 
and EG2, while those within CG are not. 
 
 
Discussion 
 
In the actual research within the subjects of all 
three groups having one or more chronic respiratory 
symptoms and spirometric impairment, we have 
measured CRP as a marker of chronic inflammation. 
The main finding of the present study is that CRP 
levels were raised in stable COPD patients 
independent of smoking habit or exposure duration. 
The mean CRP serum concentrations were higher in 
the subjects of EG1 and EG2 compared with those in 
CG, but without reaching statistical significance. This 
count for mean CRP serum concentrations in subjects 
of EG1 and EG2 exposed more than 20 years and for 
those in smokers in all three groups as well. The 
mean CRP serum concentrations were significantly 
higher in subjects with COPD within EG1 and EG2, 
while those in CG were not. This finding is by the 
results of many studies on COPD and markers of 
chronic inflammation within the general population, 
but also in certain groups of exposed workers. Aksu et 
al. reported a significantly higher CRP serum levels 
among subjects in the rural areas of Turkey exposed 
to biomass fuels [7], compared with the control group. 
The study by Pinto-Plata et al. did not find a 
correlation between CRP serum levels and smoking, 
while it significantly decreases in subjects on 
continuous therapy with inhaled corticosteroids [13].  
 Several studies on COPD have demonstrated 
an influx of immune cells, both in the airway wall and 
lumen, the alveoli and pulmonary vessels [24]. 
Disease severity is associated with increased airways 
inflammation [25]. Many studies have shown that 
COPD patients have higher levels of some 
inflammatory markers in blood, notably C-reactive 
protein (CRP) [26–29], fibrinogen [30], and the 
inflammatory cytokines interleukin (IL)-6 [29, 31] and 
IL-8 [32, 33], respectively. For tumour necrosis factor 
(TNF) results are conflicting, as some studies [31, 34] 
have found higher TNF-a levels among COPD 
patients, whereas some studies have not [31, 35]. It 
has been suggested that systemic inflammation may 
explain part of the heterogeneity of COPD 
phenotypes, such as loss of lean body mass [36], and 
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the higher prevalence of co-morbid disorders such as 
coronary heart disease, depression and hypertension 
[37, 38]. 
 Elevated serum CRP levels indicating a low 
grade persistent systemic inflammation in COPD 
patients was first described in early 2000’s [39, 40]. 
Then the positive relationship between CRP levels 
and important prognostic clinical variables in stable 
COPD patients was reported in 2006 by de Torres et 
al. [11]. These results indicate that systemic 
inflammation is related to the disease severity and 
physiological parameters should be considered in 
evaluating the COPD patients instead of focusing only 
on lung function indices. The airflow limitation in 
COPD is associated with the abnormal inflammatory 
response of the lung to noxious particles or gases. 
Farming exposure to noxious respiratory particles 
remains still a burning issue in most countries, 
independently of the degree of economic growth and 
preventive equipment used. Cigarette smoking, on the 
other hand, is still the most commonly encountered 
risk factor [41]. It is probable that such as in the case 
of smoking, exposure in farming also disturbs the 
cellular oxidant-antioxidant balance and initiates the 
inflammatory process in the lungs of COPD patients. 
To our knowledge, the effect of such exposure on 
serum CRP levels has not been studied previously. As 
mentioned above, in the present study no significant 
difference in serum CRP concentrations was detected 
between the subjects grouped according to smoking 
status and to farming exposure duration. About these 
findings, we confirm that elevated CRP concentrations 
in subjects with COPD were due to the ongoing 
inflammatory status and are independent of the 
smoking habit or farming exposure. High CRP levels 
have been shown to be associated with all-cause, 
cardiovascular, and cancer specific causes of 
mortality [39] thus reflect poor prognosis in COPD 
patients. Opposed to some previous reports, declaring 
that the use of inhaled corticosteroids decreases 
serum CRP levels [6, 13], our study was unable to 
confirm any significant difference in serum CRP 
concentrations between subjects with COPD who 
were on inhaled corticosteroid therapy and those who 
were not. This is not surprising since the recent 
reports came along denying any reduction in systemic 
inflammation in COPD with the use of inhaled 
corticosteroids [42, 43]. 
Our present study has some limitations. 
Namely, relatively small number of the subjects in the 
study groups may be a limitation, with possible 
implications on the data obtained and its 
interpretation, especially in their possible interpolation 
on the population level for the agricultural workers in 
R. Macedonia. Also, there is a lack of ambient 
monitoring and exposure measurement (endotoxin, 
dust, gases, vapours, and chemicals) in this survey, 
but the data are based on specially designed 
questionnaire and job exposure matrices, which were 
introduced in our country.  
Finally, we can conclude that systemic 
inflammation is present in farmers with COPD and 
CRP is an important biomarker in COPD in means of 
reflecting disease severity and prognosis of exposed 
farmers. Serum CRP levels were raised independently 
of smoking status and farming exposure duration in 
COPD patients reflecting that CRP rise was a result of 
the inflammatory nature of the disease itself. Further 
trials must be performed to investigate this 
relationship, but also having in mind exposure 
duration and its characteristics in farming, as well.  
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